El-Nasr Pharmaceutical Chemicals company had been constructed in 1960. The main objective to establish this company is to secure the Arab countries’ strategic needs from pharmaceutical raw materials, chemicals and antibiotics that should be available permanently because of its strategic importance  as a primary material needed by drug industry.

In May 1964, the Egyptian Ex- former President “Gamal Abdel Nasser” and the Soviet Ex-former President “Khruchouf” paid a visit to open the company that was considered as the primary nucleus planted for the city of medicine.

Thus; since then, the production of raw materials and basic chemicals for the pharmaceutical industry was realized for the first time in Egypt and the entire region.

Nasr Company for Pharmaceutical Chemicals is distinguished as the primary one in Egypt, Middle East and Africa because of its uniqueness in the production of organic and non-organic pharmaceuticals, veterinary medicine and veterinary raw materials, In addition to the production of  parenteral and dialysis solutions , dialysis  filters and the needed medical appliances necessary for packaging of large volume parenteral.

The company is keen to update and modernize their production lines regularly in accordance to the latest requirements of GMP and Egyptian Ministry of Healthguidelines.

The company is actively interested in exportation of its products to many Arab and African markets. 

website

www.elnasrpharma.com

products company catalog

download

products company profile

download

Board Members:

Dr/ Khaled shaban mansor                               Manging Director 

Dr/Ashraf Sameeh Sadek                                    Chairman of the Board 

Mr/ Salem sadek abo elmaati                               Member

Mr/ Ahmed Saad  Galal Member                            Member

Mr/ mohamed Abdel Maksoud mohamed                  Elected member

Audit Committee:

Company Main Indicators (in thousands of Egyptian Pounds)

Indicator2017-20182018-20192019-2020
Net Operating Revenue447148465747495629
Interest Expenses421542304015964
Net Income(85721)(80874)(104139)
Net Equity694025984(88039)
Working Capital(156978)(273346)(337265)
Total Investment741644777435817511
Salaries205642208681221620
Number of workers240322832156